Phlow receives approval to join BARDA CDMO network

US start-up Phlow has been approved to join the Biomedical Advanced Research and Development Authority's (BARDA) CDMO network to provide domestic API manufacturing capability for essential medicines and medical countermeasures.

As part of the US government's BARDA network, Phlow will play its part in providing a domestically integrated, systematic approach to develop the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.

Network members are highly vetted manufacturers that are prequalified and ready to immediately deliver key medicines for the benefit of all Americans, while at the same time reducing the nation’s reliance on imports from foreign nations.

Currently, the CDMO is working with BARDA to put a US-based essential medicines supply chain solution into operation by developing APIs.

To improve the development and manufacturing of APIs and finished pharmaceutical products, Phlow is employing state-of-the-art green chemistry, continuous flow technology, and other advanced manufacturing processes.

Eric Edwards, president, co-founder, and CEO of Phlow said they, together with the US government, will ensure "preparedness for future national health crises".